Gluten sensitivity among the patients with Inflammatory Bowel Disease and the possibility of therapeutic effect of gluten free diet
Not Applicable
- Conditions
- Inflammatory Bowel Disease
- Registration Number
- JPRN-UMIN000034187
- Lead Sponsor
- hyogo medical college department of psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
patinet who can't provide written informed consent patient with severe cardiac or liver insufficiency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of gluten sensitivity is determined by the antibody levels of tissue transglutaminase IgA antibody, the deamidated gliadin peptide IgA antibody, gliadin IgA antibody, gliadin IgG anti body. The effectiveness of gluten free diet is assessed by CDAI, Lichtiger Index, GAD-7, PHQ-9 and PHQ-15 before and two weeks later of taking gluten free diet. Improved patients is assessed at four and eight weeks.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What immune pathways or gut microbiota changes are associated with gluten sensitivity in IBD patients in JPRN-UMIN000034187?
How does a gluten-free diet compare to anti-TNF therapy in managing IBD inflammation in JPRN-UMIN000034187?
Which HLA or cytokine biomarkers predict response to gluten-free diet in IBD patients from JPRN-UMIN000034187?
What nutritional deficiencies or gastrointestinal side effects arise from gluten-free diet in JPRN-UMIN000034187 IBD patients?
Are there synergistic effects of combining gluten-free diet with probiotics or prebiotics in JPRN-UMIN000034187 IBD management?